HK Stock Market Move | CSTONE PHARMA-B (02616) surged over 6% in the afternoon after being included in the list of securities eligible for Hong Kong Stock Connect. Major international banks have successively expressed optimism about the company's development prospects.

CSTONE PHARMA-B (02616) rose over 6% in the afternoon, and as of press time, it was up 5.27%, trading at HKD 6.385 with a transaction volume of HKD 82.0973 million. In news, CSTONE PHARMA-B announced that its shares have been included in the list of eligible securities for the Hong Kong Stock Connect, effective from September 7, 2026. The companys core asset, the PD-1/VEGF/CTLA-4 trispecific antibody CS2009, is progressing efficiently in global Phase I/II clinical trials, with the expectation to initiate the first global Phase III registration clinical trials by the end of 2026. Additionally, the global Phase I clinical trial for the companys self-developed EGFR/HER3 bispecific ADC CS5007 has also been launched, which will be conducted simultaneously in China and Australia. It is noteworthy that recently, major international investment banks Jefferies and Goldman Sachs have released research reports optimistic about CSTONE PHARMA-B's development prospects. The core logic points to the continued improvement in the clinical data of the companys self-developed pipeline CS2009, opportunities for business development abroad, the impending launch of intensive global multi-regional clinical trials (MRCT) by the end of the year, and the company's high-quality operating performance in the first half of the year. Goldman Sachs estimates that the next 6 to 12 months will be a critical period for the realization of key catalysts for CSTONE PHARMA.